Abstract 425P
Background
In Indonesia, traditional medicine is still trusted, especially as a cancer therapy. Cancer treatment, which has many side effects, triggers the patient's anxiety. The patient's decision may contradict the advice of a health professional, affecting the prognosis of cancer. Health professionals are responsible for delivering explicit and adequate information to prevent misinformation that may affect decision-making for patient care. The Universitas Sebelas Maret Trust and Readiness Assessment for Cancer Patients (UNS – TRAfCP35) is an instrument designed to assess a patient's understanding of cancer, confidence in alternative medicine, and a patient's confidence in medical therapies. This study aims to see the validity and reliability of UNS – TRAfCP35 in assessing patients' understanding of cancer, trust in alternative medicine, and trust in medical treatment for cancer patients in Indonesia.
Methods
This is a cross-sectional hospital-based study conducted on 100 patients at Dr. Moewardi Hospital, using UNS-TRAfCP35. The questionnaire consisted of 35 questions divided into 3 parts: 15 questions regarding patients' understanding of cancer, 8 questions regarding their belief in alternative medicine, and 12 questions about patients' trust in medical treatment. Validity and reliability were used using Pearson and Cronbach alpha.
Results
Validity tests showed that the understanding of cancer (r = 0.236–0.456), the patient's confidence in alternative medicine (r = 0.301–0.688) and the patient's confidence in medical care (r = 0.324–0.765) had r > 0.196. Reliability tests showed that the questions from each section had Cronbach alpha values of 0.712, 0.830, and 0.844, respectively. Alfa Cronbach > 0.60. The values indicate that all questions in the questionnaire are valid, reliable, consistent, and qualified for further analysis for the treatment of cancer patients.
Conclusions
This study shows that UNS – TRAfCP35 is valid and reliable for assessing patients' understanding of cancer, trust in alternative medicine, and medical care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO24 - Long-term Response to aumolertinib in NSCLC Harboring EGFR Mutation and High PD-L1 Expression: Case Report
Presenter: Wanwan Cheng
Session: Poster viewing 06
YO25 - Aumolertinib treatment in L858R patient with brain metastases: A long-term survival Case Report
Presenter: Ling Xin Feng
Session: Poster viewing 06
YO26 - Treatment of ALK positive metastatic adenocarcinoma lung - A case report of sequencing therapy.
Presenter: Rajashree ashwath
Session: Poster viewing 06
YO28 - Successful Multimodal Treatment of an Advanced Case of Axillary Synovial Sarcoma
Presenter: Paula Franco
Session: Poster viewing 06
YO29 - Asymptomatic Mesenteric Desmoid Fibromatosis: A Diagnostic and Therapeutic Challenge
Presenter: Paula Franco
Session: Poster viewing 06
YO30 - Demographic, Clinical Profile and Outcomes of Cancer Patients with Covid-19 Infection In a Tertiary Hospital Davao City: A Case Series
Presenter: Perlita Joanne Yu
Session: Poster viewing 06